Another possible explanation is that stimulatory signals on tumour progression can be transduced through diverse pathways involving different downstream molecules transducting growth and survival-promoting signals of tumour, such as KRAS, or those in the PI3K/AKT axis signalling pathways, immune to the blocker binding on a certain target [65]. The gene discussed is KRAS; the disease is neoplasm.